Review
Nature Reviews Drug Discovery 7, 841-853 (October 2008) | doi:10.1038/nrd2665
There is a Corrigendum (1 June 2009) associated with this article.
Sirtuins — novel therapeutic targets to treat age-associated diseases
Siva Lavu1, Olivier Boss1, Peter J. Elliott1 & Philip D. Lambert1 About the authors
Abstract
Sirtuins post-translationally modulate the function of many cellular proteins that undergo reversible acetylation–deacetylation cycles, affecting physiological responses that have implications for treating diseases of ageing. Potent small-molecule modulators of sirtuins have shown efficacy in preclinical models of metabolic, neurodegenerative and inflammatory diseases, and so hold promise for drug discovery efforts in multiple therapeutic areas. Here, we discuss current knowledge and data that strengthens sirtuins as a druggable set of enzymes for the treatment of age-associated diseases, including activation of SIRT1 in type 2 diabetes.
- View At a Glance
Author affiliations
- Sirtris Pharmaceuticals, a GSK Company, 200 Technology Square, Cambridge, Massachusetts, 02139, USA.
Correspondence to: Philip D. Lambert1 Email: plambert@sirtrispharma.com
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Research HighlightsNature Chemical Biology News and Views (01 Feb 2006)
Medicine Grapes versus gluttonyNature News and Views (16 Nov 2006)
See all 7 matches for News And ViewsRESEARCH
Modulation of NF-κB-dependent transcription and cell survival by the SIRT1 deacetylaseThe EMBO Journal Article (16 Jun 2004)
See all 37 matches for Research
